| Company/Division name | Sorrento Therapeutics, Inc. |
| Parent company | Sorrento Therapeutics, Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | Outsourced |
| City reshored to: | San Diego |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | COVISTIX COVID-19 Virus Rapid Antigen Detection Te |
| What non-domestic negative factors made offshoring less attractive? | Other |
